Obesity : The Microbiome at the Intersection of Nutrition and Pharma

With more than one billion people living with obesity worldwide—and its economic burden projected to reach $4.32 trillion annually by 2035—obesity remains one of the most pressing global health challenges of the 21st century. While GLP-1–based pharmacotherapies dominate headlines, Seventure Partners—a pioneering venture capital firm specializing in health, nutrition, and microbiome innovation through its dedicated Health for Life Capital funds—is releasing a scientific report that synthesizes global advances in gut microbiome research in obesity and metabolic health, highlighting its potential to serve as a foundation for sustainable, personalized therapeutic strategies that complement and extend conventional drug-based treatments.

A Global Health and Economic Crisis

According to the World Health Organization, 2.5 billion adults were overweight in 2022, including 890 million living with obesity. The World Obesity Atlas 2025 reports that this number has now surpassed one billion. If current trends continue, the WHO projects that 60% of adults will be affected by 2050. The World Obesity Federation estimates that the economic impact of overweight and obesity—including healthcare costs, lost productivity, and premature mortality—will reach $4.32 trillion annually by 2035, equivalent to nearly 3% of global GDP, comparable to the economic impact of COVID-19 in 2020.   In this context, GLP-1 (glucagon-like peptide-1) agonists have been hailed as a major breakthrough. The global market for these treatments is expected to reach $105 billion by 2030. However, this therapeutic class, as promising as it may be, also presents certain limitations that the scientific community is documenting with increasing precision.

The Limitations of Exclusively Drug based Approaches

		The Seventure Partners report highlights several unmet needs with current GLP-1 treatments. Clinical studies reveal that fewer than 50% of patients continue their treatment beyond 12 weeks, raising the critical question of result durability. Weight loss effects remain contingent on continuous medication use.   Furthermore, these therapies profoundly alter the intestinal ecosystem. GLP-1 agonists change how food transits through the gut and its fermentation patterns, which can disrupt microbiome composition. Other documented effects include loss of muscle mass (not just fat mass), frequent gastrointestinal disorders, and nutritional deficiencies linked to reduced appetite.

	"These findings do not call into question the proven benefits of GLP-1s, but they underscore the need for complementary and supplementary approaches to ensure healthy and sustainable weight loss over the long term," the report states.

	The Microbiome: An Underutilized Physiological Lever

	This is precisely where the gut microbiome offers major opportunities. GLP-1 is not just a pharmaceutical molecule—it is a hormone naturally produced by L-cells in the intestine. And this production is directly modulated by the microbiome.   Recent scientific research demonstrates that gut microbiome metabolites—particularly short-chain fatty acids (SCFAs)—naturally stimulate GLP-1 secretion. In other words, a healthy microbiome can activate the same metabolic pathways as medications, through physiological mechanisms.   The Seventure Partners report thus identifies the microbiome as a cornerstone of holistic, sustainable therapeutic strategies guided by precision medicine. This approach does not aim to replace existing treatments but to complement them and optimize their long-term effectiveness.

	A Rapidly Maturing Market

	This convergence of microbiome and metabolism is opening a high-growth market segment. According to analyses by ResearchAndMarkets and Global Industry Analysts, the global microbiome therapeutics market is expected to grow from $1.4 billion in 2024 to $21.5 billion by 2030, representing annual growth of nearly 57%. The obesity segment shows one of the strongest dynamics with a CAGR of 56.8%, alongside opportunities in oncology, chronic and age-related diseases, and gut-brain axis applications (neurodegenerative diseases, mental health, etc.).   For comparison, the GLP-1 agonist market is expected to reach $105 billion by 2030 (Morgan Stanley). The 1-to-5 ratio between these two markets illustrates both the maturity of pharmacological approaches and the significant catch-up potential of microbiome-based solutions.   Europe shows annual growth of 35.4% in this segment (Grand View Research), driven notably by public-private partnerships and the European Commission's 2025 Biotechnology Roadmap, which prioritizes microbial therapeutics for health and sustainability.

	A Broad Range of Therapeutic Innovations

	Isabelle de Cremoux's analysis maps the various product categories under development in this field: fecal microbiota transplantation (FMT), Microbiome Restoration Therapy (MRT), live biotherapeutic products (LBPs), next-generation probiotics, prebiotics, postbiotics, and functional dietary fibers. These innovations follow distinct regulatory pathways and offer complementary mechanisms of action.   A key finding emerges from the report: the need for personalized approaches. The variability in individual responses to microbiome-based treatments requires consideration of each patient's baseline microbiome composition and functions. This heralds the advent of precision medicine applied to obesity.

	Research Priorities to Be Strengthened

	The report also identifies priority research areas to accelerate the clinical translation of these approaches: filling remaining mechanistic gaps, prioritizing randomized clinical trials in humans over animal experimentation, and standardizing methodologies for microbiome data collection and analysis.

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)